The use of selective serotonin reuptake inhibitors in autism and related disorders

David J. Posey, Craig A. Erickson, Kimberly A. Stigler, Christopher J. McDougle

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

This paper reviews the published literature on the use of selective serotonin reuptake inhibitors (SSRIs) for the treatment of symptoms associated with autistic disorder and other pervasive developmental disorders (PDDs) in both children and adults. To date, placebo-controlled studies of SSRIs have involved only fluvoxamine (in children and adults) and fluoxetine (in children). Open-label and retrospective studies of all other SSRIs in PDDs have also been published that suggest effectiveness. Despite these positive reports, there continues to be questions about the tolerability and appropriate dosing of SSRIs in children with PDDs. Because of the limited number of placebo-controlled studies, definitive conclusions about the role SSRIs should play in the clinical treatment of children with PDDs cannot be drawn. Larger, placebo-controlled studies of SSRIs are needed to guide clinical treatment.

Original languageEnglish
Pages (from-to)181-186
Number of pages6
JournalJournal of Child and Adolescent Psychopharmacology
Volume16
Issue number1-2
DOIs
StatePublished - Feb 2006

Fingerprint

Serotonin Uptake Inhibitors
Autistic Disorder
Placebos
Fluvoxamine
Fluoxetine
Therapeutics
Retrospective Studies

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Psychiatry and Mental health
  • Pediatrics, Perinatology, and Child Health
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

The use of selective serotonin reuptake inhibitors in autism and related disorders. / Posey, David J.; Erickson, Craig A.; Stigler, Kimberly A.; McDougle, Christopher J.

In: Journal of Child and Adolescent Psychopharmacology, Vol. 16, No. 1-2, 02.2006, p. 181-186.

Research output: Contribution to journalArticle

Posey, David J. ; Erickson, Craig A. ; Stigler, Kimberly A. ; McDougle, Christopher J. / The use of selective serotonin reuptake inhibitors in autism and related disorders. In: Journal of Child and Adolescent Psychopharmacology. 2006 ; Vol. 16, No. 1-2. pp. 181-186.
@article{3922beb6934a4cc98ee7e47b084706fe,
title = "The use of selective serotonin reuptake inhibitors in autism and related disorders",
abstract = "This paper reviews the published literature on the use of selective serotonin reuptake inhibitors (SSRIs) for the treatment of symptoms associated with autistic disorder and other pervasive developmental disorders (PDDs) in both children and adults. To date, placebo-controlled studies of SSRIs have involved only fluvoxamine (in children and adults) and fluoxetine (in children). Open-label and retrospective studies of all other SSRIs in PDDs have also been published that suggest effectiveness. Despite these positive reports, there continues to be questions about the tolerability and appropriate dosing of SSRIs in children with PDDs. Because of the limited number of placebo-controlled studies, definitive conclusions about the role SSRIs should play in the clinical treatment of children with PDDs cannot be drawn. Larger, placebo-controlled studies of SSRIs are needed to guide clinical treatment.",
author = "Posey, {David J.} and Erickson, {Craig A.} and Stigler, {Kimberly A.} and McDougle, {Christopher J.}",
year = "2006",
month = "2",
doi = "10.1089/cap.2006.16.181",
language = "English",
volume = "16",
pages = "181--186",
journal = "Journal of Child and Adolescent Psychopharmacology",
issn = "1044-5463",
publisher = "Mary Ann Liebert Inc.",
number = "1-2",

}

TY - JOUR

T1 - The use of selective serotonin reuptake inhibitors in autism and related disorders

AU - Posey, David J.

AU - Erickson, Craig A.

AU - Stigler, Kimberly A.

AU - McDougle, Christopher J.

PY - 2006/2

Y1 - 2006/2

N2 - This paper reviews the published literature on the use of selective serotonin reuptake inhibitors (SSRIs) for the treatment of symptoms associated with autistic disorder and other pervasive developmental disorders (PDDs) in both children and adults. To date, placebo-controlled studies of SSRIs have involved only fluvoxamine (in children and adults) and fluoxetine (in children). Open-label and retrospective studies of all other SSRIs in PDDs have also been published that suggest effectiveness. Despite these positive reports, there continues to be questions about the tolerability and appropriate dosing of SSRIs in children with PDDs. Because of the limited number of placebo-controlled studies, definitive conclusions about the role SSRIs should play in the clinical treatment of children with PDDs cannot be drawn. Larger, placebo-controlled studies of SSRIs are needed to guide clinical treatment.

AB - This paper reviews the published literature on the use of selective serotonin reuptake inhibitors (SSRIs) for the treatment of symptoms associated with autistic disorder and other pervasive developmental disorders (PDDs) in both children and adults. To date, placebo-controlled studies of SSRIs have involved only fluvoxamine (in children and adults) and fluoxetine (in children). Open-label and retrospective studies of all other SSRIs in PDDs have also been published that suggest effectiveness. Despite these positive reports, there continues to be questions about the tolerability and appropriate dosing of SSRIs in children with PDDs. Because of the limited number of placebo-controlled studies, definitive conclusions about the role SSRIs should play in the clinical treatment of children with PDDs cannot be drawn. Larger, placebo-controlled studies of SSRIs are needed to guide clinical treatment.

UR - http://www.scopus.com/inward/record.url?scp=33645825616&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645825616&partnerID=8YFLogxK

U2 - 10.1089/cap.2006.16.181

DO - 10.1089/cap.2006.16.181

M3 - Article

C2 - 16553538

AN - SCOPUS:33645825616

VL - 16

SP - 181

EP - 186

JO - Journal of Child and Adolescent Psychopharmacology

JF - Journal of Child and Adolescent Psychopharmacology

SN - 1044-5463

IS - 1-2

ER -